GlassScriptPhysician profile
Mohammed I Baig
NPI 1043209125
$667.95
in general payments reported to CMS, 2019-2025
12 companies · $111 in 2025
The $111 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $177 · 2021: $37.46 · 2023: $14.37 · 2024: $95.50 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.42 | 2019-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $112.77 | 2019 | |
| Biotronik INC. | $45.52 | 2020 | |
| Cequr Corporation | $45.47 | 2023-2024 | Cequr Simplicity |
| Pfizer INC. | $31.03 | 2020-2021 | |
| Lilly USA, LLC | $26.43 | 2025 | Mounjaro |
| Abbott Laboratories | $22.58 | 2024 | Freestyle Libre |
| Neurocrine Biosciences, INC. | $21.83 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $21.04 | 2024 | |
| Dexcom, INC. | $20.78 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.02 | 2019 | |
| Beta Bionics, INC. | $14.06 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.